Drug Approval | December 18, 2025
FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer
Patients with BRCA mutations often face aggressive disease and poor prognosis
Patients with BRCA mutations often face aggressive disease and poor prognosis
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
Growing patent filings and tier-2 innovators reflect expanding national research base
Patients can now get the starting 2.5 mg dose for $299 per month
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Renalyx will continue operating as an independent unit within the group
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Subscribe To Our Newsletter & Stay Updated
